Literature DB >> 22310878

Antifibrotic role of HGF in sarcoidosis.

Martin Faehling1, Martin Hetzel, Diana Anders, Gerlinde Trischler, Max Bachem.   

Abstract

BACKGROUND: Pulmonary sarcoidosis has a variable course ranging from self-limiting disease to progressive fibrosis. Activation of fibroblasts, myofibroblast transformation, and matrix production may contribute to pulmonary damage in sarcoidosis. These processes are influenced by pulmonary cytokines which can be measured in bronchoalveolar lavage fluid (BALF). In order to clarify the incompletely understood fibrotic process in sarcoidosis, we classified activity of sarcoidosis according to WASOG criteria, measured TNF-α, IL-6, and HGF in BALF, and assessed the effect of HGF and BALF on proliferation and matrix production of human lung fibroblasts.
RESULTS: BALF was obtained from 34 consecutive patients with sarcoidosis. BALF of active sarcoidosis contained elevated levels of TNF-α, HGF, and IL-6 and stimulated fibroblast proliferation. BALF of inactive sarcoidosis, but not of active sarcoidosis, stimulated the production of matrix proteins. HGF levels in inactive sarcoidosis were below those of control patients. HGF suppressed TGF-β-induced matrix expression and transformation of fibroblasts into myofibroblasts.
CONCLUSION: Prevention of TGF-β-induced myofibroblast transformation may account for the inhibitory effect of HGF on matrix production. The strong fibrogenic effect of BALF of inactive sarcoidosis corresponds to the worse clinical course of inactive sarcoidosis compared with active disease and may be related to a lack of protective HGF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310878     DOI: 10.1007/s00408-012-9372-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  45 in total

Review 1.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

Review 2.  Hepatocyte growth factor: from diagnosis to clinical applications.

Authors:  Hiroshi Funakoshi; Toshikazu Nakamura
Journal:  Clin Chim Acta       Date:  2003-01       Impact factor: 3.786

3.  Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis.

Authors:  A Verstraeten; M Demedts; J Verwilghen; A van den Eeckhout; G Mariën; L M Lacquet; J L Ceuppens
Journal:  Chest       Date:  1990-09       Impact factor: 9.410

4.  HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis.

Authors:  Shinya Mizuno; Kunio Matsumoto; Ming-Yue Li; Toshikazu Nakamura
Journal:  FASEB J       Date:  2005-01-21       Impact factor: 5.191

Review 5.  Corticosteroids for pulmonary sarcoidosis.

Authors:  N S Paramothayan; T J Lasserson; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

6.  The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Authors:  Martin Sattler; Mamatha M Reddy; Rifat Hasina; Tara Gangadhar; Ravi Salgia
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

7.  Mesenchymal cell survival in airway and interstitial pulmonary fibrosis.

Authors:  James C Bonner
Journal:  Fibrogenesis Tissue Repair       Date:  2010-08-25

Review 8.  Role of CD4+ T cells in sarcoidosis.

Authors:  Johan Grunewald; Anders Eklund
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

9.  Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study.

Authors:  K Zhang; M D Rekhter; D Gordon; S H Phan
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

10.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans.

Authors:  M G Bachem; E Schneider; H Gross; H Weidenbach; R M Schmid; A Menke; M Siech; H Beger; A Grünert; G Adler
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.